NASDAQ:CPRX - Catalyst Pharmaceuticals, Inc.
$5.31
 $0.05
+0.95%
4:00PM EDT
2019-04-18
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CPRX     avg for
industry   		  avg for
sector  
42 stocks weight:  0. 10   199. 07   233. 87  
42 stocks rank:  4. 31 K 1. 43 K 1. 06 K
# analyst opinions:  6. 00   14. 48   14. 09  
quick ratio:  5. 62   5. 29   1. 92  
current ratio:  5. 80   5. 64   2. 40  
target price low:  $ 7. 00   $ 84. 50   $ 115. 74  
target price avg:  $ 8. 58   $ 110. 73   $ 137. 39  
target price high:  $ 10. 00   $ 136. 41   $ 157. 80  
1-yr high:  $ 5. 60   $ 114. 11   $ 138. 85  
last close:  $ 5. 31   $ 87. 56   $ 116. 78  
50-day avg:  $ 3. 86   $ 95. 43   $ 123. 53  
200-day avg:  $ 3. 14   $ 94. 13   $ 121. 20  
1-yr low:  $ 1. 92   $ 72. 67   $ 98. 41  
volume:  1. 33 M 2. 43 M 4. 85 M
50-day avg volume:  1. 86 M 2. 72 M 4. 97 M
200-day avg volume:  1. 39 M 2. 90 M 4. 58 M
1-day return:  0. 95 % -0. 40 % 0. 07 %
this week return:  -1. 48 % -5. 72 % -4. 11 %
12-wk return:  109. 06 % 1. 78 % -0. 04 %
52-wk return:  118. 04 % 10. 81 % 14. 09 %
enterprise value (EV):  $ 501. 31 M $ 51. 19 B $ 117. 96 B
market cap:  $ 545. 59 M $ 43. 00 B $ 104. 52 B
EBITDA:  $ -35. 26 M $ 4. 45 B $ 8. 01 B
enterprise multiple (EV/EBITDA):  -14. 22   4. 34   13. 27  
enterprise/revenue (EV/R):  1. 00 K 68. 16   13. 68  
total revenue:  $ 500. 00 K $ 10. 61 B $ 38. 24 B
total debt:  $ 0. 00   $ 12. 22 B $ 16. 66 B
net income (common):  $ -34. 00 M $ 2. 20 B $ 4. 21 B
shares outstanding:  102. 74 M 570. 91 M 1. 24 B
shares:  77. 11 M 571. 02 M 1. 23 B
shares short:  8. 62 M 9. 93 M 16. 79 M
shares short prior month:  6. 90 M 9. 96 M 16. 58 M
short ratio:  8. 44   5. 31   3. 30  
short % of float:  9. 01 % 5. 81 % 2. 61 %
total cash/share:  $ 0. 52   $ 11. 13   $ 9. 30  
total cash:  $ 53. 48 M $ 6. 70 B $ 7. 10 B
free cash flow:  $ -13. 85 M $ 3. 58 B $ 4. 74 B
operating cash flow:  $ -25. 70 M $ 4. 14 B $ 6. 32 B
book value:  $ 0. 49   $ 12. 76   $ 26. 84  
price/book:  10. 75   3. 08   -1. 74  
operating margins:  -7059. 03 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  100. 00 % 37. 02 % 55. 68 %
1-yr max volatility:  30. 35 % --- ---
1-yr mean volatility:  0. 38 % 0. 03 % 0. 04 %
1-yr EPS:  -0. 33   2. 39   4. 08  
forward EPS:  0. 24   3. 97   7. 14  
P/E:  -16. 04   13. 59   22. 83  
forward P/E:  22. 46   -20. 05   14. 49  
PE/G:  3. 59   -1. 46   1. 68  
growth:  -4. 47 % 126. 81 % 29. 29 %
earnings high:  $ -0. 10   $ 1. 02   $ 1. 63  
earnings avg:  $ -0. 13   $ 0. 76   $ 1. 51  
earnings low:  $ -0. 20   $ 0. 47   $ 1. 39  
revenue high:  $ 3. 72 M $ 2. 68 B $ 10. 71 B
revenue avg:  $ 1. 60 M $ 2. 59 B $ 10. 49 B
revenue low:  $ 300. 00 K $ 2. 49 B $ 10. 25 B
return on assets:  -30. 25 % -2. 80 % 5. 29 %
return on equity:  -51. 62 % -18. 52 % 7. 38 %
revenue/share:  0. 01   13. 27   55. 24  
beta (1yr vs S&P500):  1. 07   1. 24   0. 93  
sharpe (1yr):  1. 41   0. 29   0. 60  
held % insiders:  6. 89 % 6. 38 % 3. 38 %
held % institutions:  52. 00 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : CPRX
.    + 1.973 =         1.973 :: INITIAL WEIGHT
.   + 34.693 =        36.666 :: spline projection addition
.    x 1.432 =        52.507 :: industry recommendation factor
.     x 4.91 =       257.831 :: EV/R factor
.    x 0.997 =       257.051 :: return on assets factor
.    x 0.995 =       255.724 :: return on equity factor
.    x 2.971 =       759.756 :: current ratio factor
.    x 1.103 =       837.907 :: quick ratio factor
.    x 1.058 =       886.157 :: short ratio factor
.    x 2.221 =      1968.291 :: price-to-book factor
.    x 1.717 =      3380.207 :: 5-day avg > 200-day avg
.    x 1.399 =       4727.28 :: 5-day avg > 50-day avg
.    x 1.228 =      5804.933 :: 50-day avg > 200-day avg
.    x 1.812 =       10519.7 :: P/E weight
.    x 0.727 =      7642.571 :: PE/G factor
.    x 1.516 =      11585.92 :: beta factor
.     x 1.41 =     16331.093 :: sharpe factor
.    x 1.593 =     26011.096 :: target low factor
.    x 1.262 =     32815.091 :: target mean factor
.    x 1.094 =      35899.08 :: target high factor
.    x 1.312 =      47086.97 :: industry 2-weeks return factor
.    x 0.992 =     46691.802 :: overall "drift" factor
.    x 0.697 =     32521.656 :: largest single-day jump factor
.    x 0.084 =      2739.819 :: low price factor
.      x 1.0 =      2739.378 :: factor hist industry gain for week 15
.   cubeRoot =        13.992 :: reduced to standardize
.   - 20.633 =           0.1 :: add/subtract for performance
.                        0.1 :: FINAL WEIGHT for NASDAQ:CPRX

 

News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org